$39.94 Million in Sales Expected for Blueprint Medicines Co. (NASDAQ:BPMC) This Quarter

Wall Street analysts expect Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) to post $39.94 million in sales for the current fiscal quarter, according to Zacks. Eight analysts have made estimates for Blueprint Medicines’ earnings, with the lowest sales estimate coming in at $30.90 million and the highest estimate coming in at $53.00 million. Blueprint Medicines […]

Related Keywords

Arizona ,United States ,Stifel Nicolaus ,Ariel Hurley ,Jeffreyw Albers ,Blueprint Medicines Corporation ,Asset Management Inc ,Zacks Investment Research ,Benjaminf Edwards Company Inc ,Nasdaq ,Financial Services Group Inc ,Dupont Capital Management Corp ,Blueprint Medicines Co ,Blueprint Medicines Company Profile Get Rating ,Citigroup ,Wall Street ,Blueprint Medicines ,Get Rating ,Blueprint Medicine ,Investment Research ,Services Group ,State Retirement System ,Capital Management Corp ,Management Inc ,Medicines Company Profile ,Medicines Corporation ,Nasdaq Bpmc ,Bpmc ,Medical ,Ratings ,Consensus ,